Considering the relatively small sample size and the limited statistical power of an individual study, it is necessary to conduct a comprehensive up-to-date meta-analysis to evaluate the association between the expression of TUBB3 and the clinical outcomes of chemotherapy, such as the objective response rate (ORR), overall survival (OS), and event-free survival (EFS) in NSCLC patients receiving the taxane/vinorebine-based chemotherapy. The gene discussed is TUBB3; the disease is non-small cell lung carcinoma.